Pfizer shares preliminary findings on omicron-adapted bivalent COVID-19 booster

Early data from a Pfizer-BioNTech (NYSE:PFE/Nasdaq:BNTX) Phase 2/3 study (NCT05472038) indicate that their updated omicron BA.4/BA.5-adapted bivalent COVID-19 booster works as intended. 

After drawing sera from booster recipients seven days after administration, investigators concluded that a single 30-µg booster dose increased omicron BA.4/BA.5 neutralizing antibody levels. In addition, they note that the updated vaccine potentially offers more robust protection against those omicron sub-lineages than the original vaccine in adults. 

The updated vaccine also appeared to be well tolerated, with a safety profile similar to the companies’ first COVID-19 vaccine. 

Pfizer and BioNTech will present additional data on the bivalent vaccine one month after administration in the coming weeks. 

The study broke participants into two age groups, with the first aged 18 to 55 years old and the second group older than 55. There were 40 volunteers in each age gro…

Read more
  • 0